目的 探讨脑康泰片联合多巴丝肼治疗帕金森病的临床疗效。方法 纳入2022年7月—2025年2月徐州市中心医院接受诊治的120例帕金森病患者，按随机数字表法将患者分为对照组和治疗组，各60例。对照组口服多巴丝肼片，初始剂量62.5 mg/次，3次/d，每周递增125 mg，直至最终有效剂量，最大剂量≤250 mg/次，3次/d。治疗组在对照组基础上口服脑康泰片，3片/次，3次/d。两组疗程12周。评估两组临床疗效。比较治疗前后两组量表评分[39项帕金森病生活质量问卷（PDQ-39）评分、帕金森病睡眠量表-2（PDSS-2）评分、日常生活能力评定量表（ADL）评分]及血清脑源性神经营养因子（BDNF）、同型半胱氨酸（Hcy）、白细胞介素-6（IL-6）、谷胱甘肽过氧化物酶（GSH-Px）、丙二醛（MDA）水平。结果 治疗组总有效率是93.33%，高于对照组的80.00%（P＜0.05）。治疗后，两组统一帕金森病评定量表（UPDRS）-Ⅰ评分、UPDRS-Ⅱ评分、UPDRS-Ⅲ评分、UPDRS-Ⅳ评分、总评分均显著降低（P＜0.05）；治疗后，治疗组患者UPDRS各亚量表评分及总评分较对照组更低（P＜0.05）。治疗后，两组患者PDQ-39、PDSS-2评分和血清Hcy、IL-6、MDA都低于同组治疗前（P＜0.05）；治疗组都低于对照组（P＜0.05）。治疗后，两组ADL评分和血清BDNF、GSH-Px都显著升高（P＜0.05），并以治疗组增加为甚（P＜0.05）。结论 帕金森病应用脑康泰片联合多巴丝肼治疗安全性较好，不仅能显著提升患者的日常活动能力、睡眠状况及生活品质，还能有效抑制炎症反应和氧化损伤，对神经元具有保护效应，利于临床症状缓解和病情控制。

Objective To investigate the clinical efficacy of Naokangtai Tablets combined with levodopa and benserazide in the treatment of Parkinson’s disease (PD). Methods A total of 120 PD patients treated at Xuzhou Central Hospital from July 2022 to February 2025 were enrolled and divided into two groups according to the random number table method, with 60 cases in each group. The control group was po administered with Levodopa and Benserazide Hydrochloride Tablets at an initial dose of 62.5 mg/time, 3 times/d, with a weekly increment of 125 mg until the final effective dose (maximum dose ≤ 250 mg/time, 3 times/d). The treatment group was additionally given Naokangtai Tablets (3 tablets/time, 3 times/d) on the basis of the control group. Both groups were treated for 12 weeks. The clinical efficacy was evaluated, and changes in scale scores [39-item Parkinson’s Disease Questionnaire (PDQ-39), Parkinson’s Disease Sleep Scale-2 (PDSS-2), Activity of Daily Living (ADL) scale] and serum levels of brain-derived neurotrophic factor (BDNF), homocysteine (Hcy), interleukin-6 (IL-6), glutathione peroxidase (GSH-Px), and malondialdehyde (MDA) were compared between the two groups before and after treatment. Results The total effective rate of the treatment group was 93.33%, which was higher than that of the control group (80.00%, P < 0.05). After treatment, both groups showed significant reductions in Unified Parkinson’s Disease Rating Scale (UPDRS) subscale scores (Ⅰ, Ⅱ, Ⅲ, Ⅳ) and total score (P<0.05), with the treatment group exhibiting lower scores in all UPDRS subscales and total score compared to the control group (P < 0.05). Post-treatment, PDQ-39, PDSS-2 scores, and serum levels of Hcy, IL-6, and MDA were significantly decreased in both groups compared to pre-treatment (P< 0.05), and these indices were further reduced in the treatment group versus the control group (P< 0.05). Additionally, ADL scores and serum levels of BDNF and GSH-Px were significantly increased in both groups after treatment (P< 0.05), with more pronounced elevations observed in the treatment group (P< 0.05). Conclusion The combination of Naokangtai Tablets and levodopa and benserazide is safe and effective for PD. It not only significantly improves patients’ daily activity ability, sleep quality, and quality of life but also effectively inhibits inflammatory responses and oxidative damage, exerts neuroprotective effects, and contributes to the alleviation of clinical symptoms and disease control.

R971

徐州市卫健委2022年度医学科技创新项目（XWKYHT20220162）